ADMINISTRATION The Office of Translational Research (OTR), under the leadership of CCSG deputy director Dr. Robert Bast, coordinates and implements all administrative functions related to the CCSG. Dr. Bast has a dual reporting relationship, reporting directly to Dr. Giulio Draetta, chief scientific officer, and to Dr. Peter Pisters, MD Anderson president and CCSG PI for matters relating to the CCSG. Dr. Bast's staff provides administrative support and financial, scientific, and technical oversight for the CCSG programs; for all institutional shared resources, including CCSG core facilities; and for all other CCSG components, including Clinical Protocol and Data Management (CPDM), the Protocol Review and Monitoring System (PRMS), Community Outreach and Engagement, Career Enhancement and Related Activities, Development Funds, Senior Leadership, Planning and Evaluation, and CCSG administrative supplements. OTR staff serve on many of MD Anderson's advisory and oversight committees, including MD Anderson's Moon Shot Operations and Executive Committee and committees responsible for capital equipment allocation, oversight of research data storage, and financial controls. Administrative support is provided in the following areas: 1) business operations and financial management of shared resources; 2) central organization and coordination for the scientific and technical aspects of shared resource operations; 3) facilitation of programmatic interactions and engagement; 4) facilitation of communication between center director, program leaders, shared resource directors, and program members; 5) development, management, and maintenance of databases for program funding, program membership, program member publications, program member biographical information, and shared resource utilization; 6) allocation and monitoring of the use of CCSG development funds; 7) coordination and writing of CCSG progress reports and competitive renewal applications; and 8) organization of CCSG Executive Committee and annual External Advisory Board meetings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997791
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications